GLP-1 agonist efficacy and weight loss outcomes
Discussed in 1 analyzed podcast episode across 1 show
Discussed On
Episodes
The Top Line · Jul 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
Vertex Crinetics acquisition and rare endocrine disease expansionClinical trial regulation and China data integrity scrutinyRetatrutide triple agonist development and comorbidity benefitsOral obesity medication market competition and prescriptionsNext-generation incretin drug tolerability and dosing frequency
View Analysis